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ABSTRACT 
An ideal novel treatment for bone defects should provide regeneration without autologous or allogenous 
grafting, exogenous cells, growth factors or biomaterials while ensuring spatial and temporal control as well 
as safety. Therefore, a novel osteoinductive non-viral in vivo gene therapy approach using sonoporation was 
investigated in ectopic and orthotopic models. Constitutive or regulated doxycycline-inducible bone 
morphogenetic protein 2 and 7 co-expression plasmids were repeatedly applied for 5 days. Ectopic and 
orthotopic gene transfer efficacy was monitored by co-application of a luciferase plasmid and 
bioluminescence imaging. Orthotopic plasmid DNA distrubution was investigated using a novel plasmid 
labeling method. Luciferase imaging demonstrated an increased trend (61% vs 100%) of gene transfer 
efficacy and µCT evaluation showed significantly enhanced frequency of ectopic bone formation for 
sonoporation compared to passive gene delivery (46% vs 100%) dependent on applied ultrasound power. 
Bone formation by the inducible system (83%) was stringently controlled by doxycycline in vivo and no 
ectopic bone formation was observed without induction or with passive gene transfer without sonoporation. 
Orthotopic evaluation in a rat femur segmental defect model demonstrated an increased trend of gene 
transfer efficacy using sonoporation. Investigation of DNA distribution demonstrated extensive binding of 
plasmid DNA to bone tissue. Sonoporated animals displayed a potentially increased union rate (33%) without 
extensive callus formation or heterotopic ossification. We conclude that sonoporation of BMP2/7 co-
expression plasmids is a feasible, minimally invasive method for osteoinduction & improvement of bone 
regeneration by gene delivery being superior to passive gene delivery. 
 
 
Keywords: Sonoporation, non-viral, gene therapy, heterodimer, bone morphogenetic protein, BMP2/7, 
TetON, inducible, ectopic, orthotopic
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INTRODUCTION 
Traumatic fractures can lead to defects of critical size that can fail to regenerate completely, depending on the 
fracture site and general clinical situation of the patient (Stannard et al., 2007). These non-union fractures, 
also termed pseudoarthroses, are characterized by a failure to heal within 8-9 months (Stannard et al., 2007). 
Such a situation represents a major clinical challenge, which is still not addressed adequately by conventional 
treatment. Autologous bone grafting from the iliac crest can provide satisfying regenerative outcome, 
although at the cost of an invasive procedure requiring surgical intervention causing donor site morbidity 
(Jones CB, 2005; MK Sen, 2007). Other experimental treatment modalities include combinations of 
autologous stem cell treatment, biomaterials and growth factors (Axelrad et al., 2007; Bruder et al., 1998; 
Kanakaris and Giannoudis, 2008; Schmidmaier et al., 2008). Therapies that rely on stem cell treatment 
require invasive sampling and in vitro expansion of these cells prior to implantation, which again can lead to 
donor site morbidity and furthermore require expensive GMP facilities for safe cell enrichment and 
expansion (Verbeek, 2012). Furthermore, these procedures hold the inherent drawback of currently failing to 
be applied in a minimally invasive one-step approach. Recombinant growth factors on the other hand, are 
expensive in production (Vaibhav et al., 2007) and interestingly need to be applied in potentially dangerous 
supraphysiological doses (Gamradt SC, 2004), which can lead to adverse effects such as heterotopic 
ossification (Benglis et al., 2008) or immune responses (Hwang et al., 2009). A novel therapeutic approach 
should therefore enable a cost-effective, efficient and minimally invasive treatment of non-union fractures. It 
should preferentially be applied in a one-step procedure without the need for autologous or allogeneic 
implantation material. Several studies have demonstrated the feasibility of transient gene therapies for 
osteoinduction either through ex vivo (Gamradt SC, 2004) or in vivo viral (Bleiziffer et al., 2007 ) or non-
viral gene transfer (Bleiziffer et al., 2007; Luo et al., 2005). The main advantage of this approach is that 
endogenous cells are forced to express an osteoinductive factor in situ directly at the fracture site, leading to 
correct post-translational modifications and conformation of the factor, thereby mediating higher bioactivity 
at lower concentrations compared to application of recombinant factors (Brooks, 2006). Since non-viral in 
situ gene transfer has a much better safety profile than viral modalities, it was selected as gene transfer 
modality within this study. Ultrasound mediated gene transfer (sonoporation), a relatively novel non-viral 
strategy that relies on neutral microbubble contrast agent mediated cell permeabilisation in situ to trigger 
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uptake of plasmid DNA (Li et al., 2009; S Mehier-Humbert, 2005), appears to be superior in terms of 
reduced invasiveness and clinical translation as compared to other non-viral methods such as electroporation 
(Cemazar et al., 2006). In order to compensate for lower efficacy of this non-viral gene transfer method, a 
highly osteoinductive co-expression strategy for bone morphogenetic protein (BMP) 2 and 7 (BMP2/7), 
which has been shown to potently mediate osteogenic differentiation in vitro (Kawai et al., 2006) and in vivo 
(Kawai et al., 2006; Zhao et al., 2005), was selected to be investigated for its regenerative potential in a 
femur non-union model in rats. The work presented herein is aimed at demonstrating the feasibility of an 
ultrasound mediated (“sonoporation”) constitutive or regulated, doxycycline inducible BMP2/7 co-expression 
strategy for bone regeneration. This approach for enhanced fracture regeneration is solely relying on 
minimally invasive injection of a BMP2/7 co-expression plasmid DNA/microbubble mixture in conjunction 
with a transcutaneously applied ultrasound trigger to mediate deep within tissue in vivo non-viral transient 
gene transfer. 
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MATERIALS AND METHODS 
 
Animals 
The animal protocol review board of the City Government of Vienna, Austria approved all experimental procedures 
in accordance with Austrian law and the Guide for the Care and Use of Laboratory Animals as defined by the 
National Institute of Health. Female Hsd:Athymic Nude-Foxn1nu nude mice (n=36)  (Harlan Laboratories, Bresso, 
Italy) of approximately 12 weeks age weighing approx. 30g were used for ectopic testing in this study. 
Male Sprague-Dawley rats (n=43) (Charles River, Wilmington, MA, US) weighing approx. 450g were used for 
orthotopic testing in this study.  
 
 
Plasmids 
The inducible and constitutive single-vector BMP2/7 co-expression plasmids, pTetON-BMP2/7 and pVAX1-
BMP2/7- (Figure S1), are described elsewhere (Feichtinger et al. 2013, under review). Briefly, the constitutive 
pVAX1-BMP2/7- system was created by using a multi-expression cassette strategy with separate CMV-promoter 
driven BMP2 and BMP7 expression cassettes in divergent orientation on the FDA DNA vaccine guideline compliant 
plasmid backbone of pVAX1 (Life Technologies, Palo Alto, CA, US). The single-vector TetON inducible BMP2/7 
co-expression system pTetON-BMP2/7 was derived from the Tet-regulated co-expression system pTREtight-BI 
(Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) by cloning BMP2 and BMP7 cDNAs into the 
multiple cloning sites and additionally transferring the entire Tet-transactivator expression cassette from pTetON-
Advanced (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) to pTREtightBI, generating a TetON 
inducible expression plasmid with 3 transcriptional entities. All plasmid preps were carried out using Endo-free 
plasmid Maxi or Giga kits (Qiagen, Hilden, Germany) or plasmids were produced as endo-free preps by Plasmid 
Factory (Bielefeld, Germany). 
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Sonoporation protocols 
A SP100 Sonoporator (Sonidel Ltd, Dublin, Ireland) emitting 1MHz ultrasound was employed for sonoporative 
gene transfer in this study. The columnar beam was set at different Watt/cm2 spatial average temporal peak settings 
with an effective radiating area of 0.8 cm2 at a pulse frequency of 100Hz/100% duty cycle. 
2 Watt/cm2 treatment protocol: This protocol was a modified protocol derived from the ultrasound parameters 
applied in previous studies by Li et al. (Li et al., 2009). Daily treatment, which was repeated for 5 days consisted of 
application of 2 Watt/cm2 1MHz ultrasound at a duty cycle of 25% for 3 minutes after injection of a plasmid 
DNA/microbubble contrast agent mixture. Total energy delivered to the target site per daily treatment was 90 
Joule/cm2. 
4 Watt/cm2 treatment protocol: This protocol was a modified protocol derived from Osawa et al. (Osawa et al., 
2009). Daily treatment, repeated for 5 days, consisted of application of 4 Watt/cm2 1MHz ultrasound at a duty cycle 
of 50% for 1min followed by a pause of 1min to prevent tissue overheating and was repeated for a total of 5 times 
(5x 1min treatment at 1 min intervals). Total energy delivered to the target site per day was 600 Joule/cm2. 
Animals were placed on a neoprene adsorber pad (Sonidel Ltd, Dublin, Ireland) with ultrasound contact gel 
(Aquasonic 100, Parker Laboratories Inc. Fairfield, New Jersey) to prevent reflection of ultrasound from the exit site 
back into the tissue and subsequent potential constructive interference with passing ultrasound, which could cause 
tissue overheating and damage. 
 
Ectopic BMP2/7 sonoporation 
Constitutive BMP2/7 co-expression in vivo 
20µg constitutive co-expression plasmid pVAX1-BMP2/7- was co-delivered with 20µg of the internal luciferase 
control plasmid pCBR (Promega GmbH, Mannheim, Germany). Sonoporation was carried out using the SP100 
device and neutral, lipid-based microbubbles (MB101, Sonidel Ltd, Dublin, Ireland) at a final concentration of 
4x108/ml (50% v/v). 50µl of this plasmid-microbubble solution was injected into m. gastrocnemius in nude mice and 
immediately thereafter sonoporated. Anesthesia was initialized in an inhalation box provided with isoflurane 
(Forane®, Abbott Gesm.b.H., Vienna, Austria) (3 vol.% isoflurane-oxygen mixture) and maintained by inhalation of 
1.5-2% isoflorane –oxygen mixture. This treatment was repeated for 5 subsequent days (total therapeutic DNA dose 
100µg/animal; ~3.3mg/kg) using the same injection site. Sonoporation was carried out using either 2 Watt/cm2 (25% 
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duty cycle) or 4 Watt/cm2 (50% duty cycle) protocols in order to investigate the influence of ultrasound power 
settings on gene transfer efficacy. Hindlimbs were sonoporated for 1min 5 times using the described power settings. 
Gene transfer efficacies of sonoporated hindlimbs were compared to passive gene transfer in control hindlimbs 
without sonoporation.  In order to investigate the potential competetive influence of an internal control plasmid on 
overall bone formation efficacy, 2 Watt/cm2 sonoporations were additionally carried out without pCBR addition. 4 
weeks after the surgery the mice were sacrificed in inhalation anaesthesia (see above) by an overdose of 
thiopentalsodium (Thiopental sandoz, Sandoz GmbH, Vienna, Austria) (120 mg/kg) by intracardiac injection and 
gastrocnemius muscles were explanted for histology. 
 
Inducible BMP2/7 co-expression in vivo 
The doxycycline inducible co-expression system for BMP2/7, TetON-BMP2/7, was sonoporated in vivo using the 2 
Watt/cm2 sonoporation protocol. The inducible systems were applied without an internal pCBR luciferase control 
plasmid. Controls for passive gene delivery were set up by intramuscular injection of the plasmids. Animals in the 
induction group received 2mg/day doxycycline in 300µl Ringer’s solution intraperitoneally for 7days for induction 
of BMP2/7 co-expresssion after sonporative or passive gene transfer. Sonoporated control animals were not treated 
with doxycycline. 
 
Orthotopic BMP2/7 sonoporation 
Femur-defect model 
Anaesthesia was induced via inhalation of 2% isoflurane and maintained through an intraperitoneal injection of a 
mixture of ketaminhydrochlorid, 110 mg/kg, (Ketamidor, Richter Pharma AG, Wels, Austria) and xylazin, 12 mg/kg 
(Rompun 2%, Bayer AG, Vienna, Austria). Preoperatively, the animals received a 2 ml liquid depot of Ringer’s 
solution (Mayerhofer Pharmazeutika GmbH, Linz, Austria) mixed with 0.3 ml butafosan (Catosal, Bayer Health 
Care Austria GmbH, Vienna, Austria). Analgesia was provided via a daily subcutaneous injection of carprofen, 4 
mg/kg (Rimadyl, Pfizer Corporation GmbH, Vienna, Austria) over the course of 4 days and a subcutaneous injection 
of buprenorphin, 0.05 mg/kg, every 12 hours during the first 2 days. During surgical procedure the rats were placed 
on a thermostatic plate in a lateral decubitus position. A lateral approach was used and the femur exposed. A 
straight, 4-hole titan plate (Stryker, Duisburg, Germany) was fixed onto the anterolateral surface of the femur using 
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four cortical 7mm titan screws (Synthes, Oberdorf, Switzerland). Subsequently, a 4 mm segmental bone defect was 
inflicted by 2 parallel osteotomies in the femur’s midshaft using a gigli saw and a template. The operation wound 
was finally closed in two layers using sutures. The animals were allowed free movement for 8 weeks and were then 
sacrificed via an intracardiac injection of thiopentalsodium (Thiopental sandoz, Sandoz GmbH, Vienna, Austria) 
(120 mg/kg). Micro computertomograph (µCT) based detection of plate and/or screw dislocation at 4 or 8 weeks 
post surgery led to exclusion of the animal from µCT bone regeneration evaluation (8 out of 32 animals, 25% drop 
out).  
Constitutive BMP2/7 co-expression in vivo 
50µg constitutive co-expression plasmid pVAX1-BMP2/7- was co-delivered 3 days post surgery with 50µg of the 
internal luciferase control plasmid pCBR using sonoporation in the active gene transfer treatment group (total 
therapeutic DNA dose: 250µg; 0.5mg/kg). The luciferase control group consisted of animals sonoporated with 50µg 
of the internal luciferase control plasmid pCBR and 50µg of an empty pDNA backbone (pUK21, Plasmid Factory, 
Bielefeld, Germany) to normalize the DNA content according to the therapy group. 
The efficacy of passive gene delivery to the defect was investigated using either injections of therapeutic plasmid 
co-delivered with the internal luciferase control plasmid (50µg pVAX1-BMP2/7- + 50µg pCBR) or of the internal 
luciferase control plasmid co-delivered with a non-expressing empty plasmid (50µg pCBR + 50µg pUK21) without 
ultrasound treatment. Furthermore, we investigated the endogenous regenerative potential and union rate in an 
empty control group, which did not receive any treatment. Sonoporation was carried out using the SP100 
sonoporator and neutral, lipid-based microbubbles (MB101, Sonidel Ltd, Dublin, Ireland) at a final concentration of 
8x108/ml (75% v/v). 200µl of this plasmid-microbubble solution was injected under x-ray guidance and immediately 
after sonoporated into the femur defect site using the 4 Watt/cm2 sonoporation protocol. This treatment was repeated 
for 5 days, resulting in a total therapeutic DNA dose of 250 µg/animal (~0.5mg/kg). 
 
Plasmid DNA labelling & orthotopic detection 
In order to enable therapeutic DNA detection at the defect site for biodistribution monitoring, we applied a novel 
metabolic DNA labelling method in E.coli based on the nucleoside (2'S)-2'-deoxy-2'-fluoro-5-ethynyluridine (F-ara-
EdU) (Neef and Luedtke, 2011). pCBR plasmid DNA was labelled with F-ara-EdU using a thymidine-auxotrophic 
E.coli strain (Chi1776, DSMZ, Braunschweig, Germany) and supplementing 394 medium (Jerome et al., 2009) 
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containing 20mg/ml thymidine + 20mg/ml F-ara-EdU. Plasmids were isolated using the Endo-free Plasmid Maxi 
Kit (Qiagen, Hilden, Germany). 
A separate cohort of rats (n=7) was allocated for imaging of in situ orthotopic luciferase expression and subsequent 
plasmid DNA detection 24h post last gene transfer. Detection was carried out on decalcified paraffin sections of the 
femora using an Alexa Fluor 680 labelled azide (Life Technologies, Palo Alto, CA, US) for the Cu+ catalyzed click 
reaction described in (Neef and Luedtke, 2011). AF680 signals, specific for F-ara-EdU labelled plasmid DNA were 
detected using an Odyssey near infrared scanner (LI-COR Biosciences, Lincoln, NE, US) and confocal laser 
scanning microscopy (CLSM). In CLSM, a separate 488nm channel was used in addition to the 680nm channel in 
order to use tissue autofluorescence to enable the generation of overlay images with specific AF680 signals and 
general tissue architecture. A decalcified femur control sample without F-ara-EdU labelled plasmid DNA served as 
a negative control. 
 
Bioluminescence imaging 
All nude mice that received the internal pCBR luciferase control plasmid were imaged 24h post last gene transfer in 
order to determine gene transfer efficacies. Imaging was carried out under short inhalation anaesthesia using a 
Xenogen IVIS100 Imaging system (Caliper Life Sciences GmbH, Mainz, Germany). Mice received 5mg D-luciferin 
potassium salt (Caliper Life Sciences GmbH, Mainz, Germany) in 300µl Ringer’s solution (Mayerhofer 
Pharmazeutika GmbH, Linz, Austria) intraperitoneally before imaging. 20 minutes post D-luciferin administration, 
the mice were imaged for 2 minutes. 
Sprague-Dawley rats were imaged 24h post last gene transfer in order to determine gene transfer efficacies. Imaging 
was carried out under short inhalation anaesthesia using a Xenogen IVIS100 Imaging system. Rats received 90mg 
D-luciferin potassium salt in 3ml Ringer’s solution intraperitoneally before imaging. 30 minutes post D-luciferin 
administration, the rats were imaged for 2 minutes. 
A separate group of rats was examined for gene transfer localization at the defect site 24h post last gene transfer 
using bioluminescence imaging in vivo after surgically opening the defect site (30min post luciferin administration) 
under general anaesthesia (see “femur-defect model” above). Additionally, femora were imaged ex vivo after the rats 
were sacrificed with in general anaesthesia (see above) by an overdose of thiopentalsodium (Thiopental, Sandoz 
GmbH, Vienna, Austria) (120 mg/kg) by intracardiac injection.  Luciferase imaging was carried out after 
!∀+!
!
explantation of the femur and adjacent muscles 45min post luciferin administration. 
 
In vivo micro Computer Tomography (µCT) analysis 
In vivo µCT images of nude mouse hindlimbs were obtained using a VivaCT 75 (Scanco Medical AG, Brütisellen, 
Switzerland) 14 days and 28 days post last gene transfer under short inhalation anaesthesia. Bone volume (mm3) and 
bone mineral density (mg hydroxyapatite per cm3 (mg HA/cm3)) for 2 and 28 days were calculated using Scanco 
software and a standard density calibration phantom. 
In vivo µCT images of rat femora at 0, 4 and 8 weeks post surgery were exported into MATLAB (MATLAB version 
7.12.0. The MathWorks Inc., 2012, Natick, MA, US) for processing. In order to facilitate analysis, the volumes 
corresponding to all 3 time points were rigidly registered onto each other using a three-step approach. 
First, the supporting titanium plate was segmented using a manually determined grey-level threshold. When using 
such a simple segmentation procedure, image artefacts can lead to the erroneous segmentation of parts of the image 
as well as to the splitting of the titanium plate. To limit the influence of this onto subsequent steps of the analysis, 
only large elements of the segmentation were retained (> 3000 voxels). 
In a second step, the major directions of the titanium plate were extracted from the processed binary segmentations 
using Principal Component Analysis (PCA, (Pearson, 1901)). Rotating the volumes according to these major axes 
serves as an initialization to the final matching step. For this, we employ the Iterative Closest Point (ICP, (Besl, 
1992)) algorithm. While reliable in practice, it is well known to be susceptible to its initialization. Alignment using 
PCA assures the convergences of ICP to the correct matching between volumes.  
The rotation computed using PCA and the deformation obtained after convergence of the ICP-process are combined 
into a rigid deformation matrix. This transformation was then applied to each volume in the sequence except the 
reference, ensuring the correct correspondences of each voxel between acquisition times. 
All volumes were then represented as colour-coded overlays of the 3 time points. New bone at the defect site was 
segmented manually and quantified as bone volume/tissue (defect) volume. 
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Histology 
Gastrocnemius muscles from nude mice were excised and fixed with 4% buffered paraformaldehyde (Sigma Aldrich 
GmbH, Vienna, Austria) in phosphate-buffered saline (PBS) for 24h, transferred in 50% ethanol and stored in 70% 
ethanol at 4°C. Samples were embedded in paraffin without decalcification, and several sections of the same sample 
were stained with haematoxylin and eosin (H&E) and von Kossa staining for mineralization according to standard 
histology protocols. Localization of the internal luciferase control expression was detected using the G7451 Goat 
Anti-Luciferase (Promega GmbH, Mannheim, Germany) primary antibody in a 1:50 dilution overnight and an 
appropriate secondary peroxidase conjugated antibody ImmPRESS Anti-Goat Ig Peroxidase (Vector Labs, 
Peterborough, UK) for 30min after blocking of endogenous peroxidase activity with 3% H2O2 in Tris-buffered 
saline. Nuclear counter-staining was carried out using Mayer’s haematoxylin solution for 1min. 
 
Statistical analysis 
Results are represented as median±interquartile range unless otherwise stated. Statistical testing was carried out 
using the non-parametric Kruskal-Wallis test in conjunction with Dunn’s multiple comparison test as post-test for 
luciferase expression, ectopic bone volume and bone mineral density data. Orthotopic sonoporation luciferase 
expression data did not pass normality testing (Kolmogorov-Smirnov test) and was therefore tested with the non-
parametric Kruskal-Wallis test in conjunction with Dunn’s multiple comparison test as post-test. Orthotopic passive 
luciferase expression data passed Kolmogorov-Smirnov normality testing and therefore was tested with a two-tailed 
t-test for significance. Gene transfer efficacy data (frequency of successful gene transfer) based on luciferase 
imaging and bone formation efficacy data (frequency of successful bone formation) were tested for improvement by 
sonoporation using a one-tailed Fisher’s exact test. Bone volume per tissue volume (BV/TV) data from orthotopic 
models was confirmed to follow a Gaussian distribution and therefore tested with parametric ANOVA and Tukey’s 
test for significance. p<0.05 was considered statistically significant (* p<0.05, **p<0.01). 
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RESULTS 
 
Ectopic BMP2/7 sonoporation 
Gene transfer efficacies & luciferase gene expression   
Evaluation of gene transfer efficacy 24 hours post last gene transfer via bioluminescence activity in nude mice 
confirmed successful gene transfer in 8 out of 13 animals (61% efficacy) for passive gene delivery, 6 out of 7 
animals (85%) for 2 Watt/cm2 sonoporation and 7/7 animals (100%) for 4 Watt/cm2 sonoporation (Figure 1A). 
Bioluminescence imaging of the internal luciferase control demonstrated variable luciferase activity in all animals 
(Figure 1B) 24h post last treatment. No significant difference in bioluminescence levels was observed between 
passive gene transfer, 2 Watt/cm2 or 4 Watt/cm2 sonoporation. Sonoporation with 4 Watt/cm2 caused considerable 
skin burns at the ultrasound exit sites in contrast to the 2 Watt/cm2 protocol. 
 
Ectopic bone formation using constitutive BMP2/7 co-expression in vivo 
Passive gene delivery of the constitutive BMP2/7 co-expression plasmid pVAX1-BMP2/7- to successfully induced 
ectopic bone formation in 6 out of 13 animals (46%) (Figure 2A). Sonoporative gene delivery with either 2 or 4 
Watt/cm2 protocols successfully induced ectopic bone formation in 5 out of 7 (71%) or 7 out of 7 animals (100%) 
respectively (Figure 2A). 2 Watt/cm2 sonoporation of pVAX1-BMP2/7- without the luciferase plasmid led to bone 
formation in 6 out of 7 animals (85%) (Figure 2A). Bone volumes were variable and did not exhibit significant 
differences (Figure 3G, H). Medians of bone volumes were 0.09 mm3 at 14 days and 0.04 mm3 at 28 days post 
treatment using the constitutive co-expression systems with passive gene transfer; 0.002 mm3 (0.03 mm3 without 
pCBR addition) at 14 days and 0.17 mm3 (0.01 without CBR addition) at 28 days post treatment using the 
constitutive co-expression system with the 2 Watt/cm2 sonoporation protocol and 0.02 mm3 at 14 days and 0.01 mm3 
at 28 days post treatment using the constitutive co-expression system with the 4 Watt/cm2 sonoporation protocol. 
Bone mineral densities did not show significant differences among treatment groups and different time points post 
treatment. Medians of bone mineral densities were 179.4 mg HA/cm3 at 14 days and 238 mg HA/cm3 at 28 days post 
treatment using the constitutive co-expression systems with passive gene transfer; 160 mg HA/cm3 (201.8 mg 
HA/cm3 without pCBR addition) at 14 days and 243.6 mg HA/cm3 (230.4 mg HA/cm3 without CBR addition) at 28 
days post treatment using the constitutive co-expression system with the 2 Watt/cm2 sonoporation protocol and  
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177.4 mg HA/cm3 at 14 days and 220.7 mg HA/cm3 at 28 days post treatment using the constitutive co-expression 
system with the 4 Watt/cm2 sonoporation protocol. Ectopic bones displayed variable morphology and irregular 
shape in all observed treatment groups (representative images in Figure 3 A-F). Direct comparison of 14 day with 28 
day in vivo µCT images of the same ossicles (Figure 3 A-F) showed moderate bone remodeling and resorption. 
Histological examination of ectopic bones at 4 weeks by HE staining revealed fully developed ossicles with a 
compact layer of bone surrounding a bone marrow cavity (Figure 4A) populated by a heterogenous cell population 
consisting of adipocytes, haematopoietic myeloid progenitor cells megakaryocytes and erythrocytes (Figure 4D). 
Immunohistochemical detection of the internal luciferase control showed diffuse staining in muscle fibers 
surrounding the ectopic bone structure and strong staining of bone lining and bone marrow cells (Figure 4B). Von 
Kossa staining for mineralization furthermore confirmed the observed structures in HE staining as mineralized bone 
tissue (Figure 4C).  
 
Ectopic bone formation using inducible BMP2/7 co-expression in vivo 
Sonoporation of the inducible single-vector BMP2/7 co-expression system pTetON-BMP2/7 using the 2 Watt/cm2 
sonoporation protocol successfully induced ectopic bone formation in 5 out of 6 animals (83%) only when induced 
with 2mg of doxycycline per 48h for 7 days as observed by in vivo µCT at 14 days and 28 days post treatment. No 
bone formation was observed without application of doxycycline (0 out of 6 animals) (Figure 2B). Furthermore, no 
bone formation was observed when using passive gene transfer and induction with 2mg of doxycycline per 48h for 7 
days (Figure 2B). Ectopic bones did not show any significant differences in bone volumes (Figure 3G, H) or bone 
mineral densities compared to ectopic bones generated using the constitutive co-expression system pVAX1-
BMP2/7- at 14 and 28 days post treatment. Medians of bone volumes were 0.1 mm3 at 14 days and 0.01 mm3 28 
days post treatment using the inducible co-expression system with the 2 Watt/cm2 sonoporation protocol.  Medians 
of bone mineral densities were 149.7 mg HA/cm3 at 14 days and 249.6 mg HA/cm3 at 28 days post treatment. 
 
Orthotopic BMP2/7 sonoporation 
Orthotopic luciferase gene expression & gene transfer efficacies 
Orthotopic bioluminescence imaging demonstrated strong luciferase expression limited to the defect site (Figure 5B, 
C, D) and no activity in adjacent muscle tissue (Figure 5C). No difference in localization and gene expression levels 
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was observed between sonoporation and passive gene transfer (Figure 1D). A significant reduction of 
bioluminescence was observed for both passive gene transfer and sonoporation when the luciferase plasmid was co-
administered with pVAX1-BMP2/7- (Figure 1D), indicating potential competitive expression. Gene transfer 
efficacies estimated via bioluminescence imaging were 66% (6 out of 9 animals) for passive gene transfer and 85% 
(12 out of 14 animals) for the 4 Watt/cm2 sonoporation group (Figure 1C). 
 
Orthotopic F-ara-EdU labeled luciferase plasmid DNA distribution 
Detection of luciferase plasmid DNA biodistribution 24h post last gene transfer at the defect site through near 
infrared scanning (Figure 6A) revealed extensive signals in bone tissue. In depth examination through CLSM 
demonstrated the confined presence of plasmid DNA within cells of the bone marrow (Figure 6B), at the defect site 
granulation tissue (Figure 6C), diffuse distribution of plasmid DNA within intact bone tissue (Figure 6D) and weak 
diffuse signals in surrounding muscle fibers (Figure 6E) with confined signals in satellite cells (Figure 6E, arrows). 
No differences in biodistribution were observed between passive gene transfer and sonoporation groups. 
 
Orthotopic bone regeneration using constitutive BMP2/7 co-expression in vivo 
In vivo µCT images of defects at 4 and 8 weeks post surgery showed 3 potential unions with substantial bone growth 
out of 6 animals of the sonoporation treatment group (Figure 7A), 1 potential union in the passive gene transfer 
treatment group (Figure 7B), 1 potential union in the luciferase control group (Figure 7C) and 1 potential union in 
the empty control group (Figure 7D) at 8 weeks post surgery. In depth examination of the µCT images at different 
angles and cut planes confirmed 2 unions out of 6 animals (33% union rate, Figure 8A) in the treatment group 
(Figure 7A, asterisks) and 1 union (16% union rate. Figure 8A) in the passive gene transfer treatment group (Figure 
7B, asterisk) at 8 weeks post surgery. No unions were confirmed (Figure 8A) in the luciferase control and empty 
control groups 8 weeks post surgery (Figure 7C, D). Quantification of bone volume/tissue volume at the initial 
margins of the defect did not show any significant differences between treatment groups and controls at both 4 
weeks (Figure 8B) and 8 weeks (Figure 8C) post surgery. 
 
DISCUSSION 
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The aim of this study was to evaluate constitutive or regulated, doxycycline inducible, non-viral sonoporative 
BMP2/7 gene co-delivery in vivo for bone regeneration.  It has been demonstrated that the repeated co-delivery of a 
highly bioactive BMP2/7 gene-combination effectively mediates bone formation in vivo and that gene expression 
can be precisely controlled. Direct comparison of sonoporation with passive gene delivery demonstrated an 
increased probability of gene expression and bone formation dependent on total ultrasound energy applied, whereas 
when successful gene transfer was accomplished, gene expression levels and bone volumes were not increased via 
sonoporation. In orthotopic models, a beneficial effect of sonoporation on gene transfer probabilities was indicated 
and to localized orthotopic gene expression was achieved. DNA tracking revealed that a large fraction of plasmid 
DNA binds to intact bone and is thus absorbed from the defect site. In vivo µCT data suggests enhanced orthotopic 
bone regeneration after active sonoporative gene transfer of BMP2/7 to the target site. 
 
Ectopic BMP2/7 sonoporation 
Ectopic gene transfer monitoring with luciferase showed that the rate of successful gene transfer can be increased 
compared to passive gene delivery when applying ultrasound of increasing power (Figure 1A). It was possible to 
reach gene transfer efficacies of 100% using the 4 Watt/cm2 (600 Joule/cm2) sonoporation protocol, however there 
were no significant differences in expression levels observed between passive gene transfer and sonoporation 
(Figure 1B). Therefore, we conclude that sonoporation increases gene transfer efficacy compared to passive gene 
delivery and that the efficacy depends on the applied ultrasound power. This is in line with findings demonstrated in 
(Li et al., 2009), showing that in vitro there is a delicate balance between ultrasound power, cell viability and 
sonoporation efficacy. We observed skin burning at the exit sites of ultrasound in the 4 Watt/cm2 protocol in nude 
mice, which has not been reported in (Osawa et al., 2009), which used an outbred mice strain in which skin damage 
is less obvious. This phenomenon disappeared when ultrasound power was reduced from 600 Joule/cm2 to 90 
Joule/cm2 using the 2 Watt/cm2 protocol. Bone formation efficacies of the different gene transfer protocols (Figure 
2) generally paralleled gene transfer efficacies observed by luciferase monitoring (Figure 1A) improving 
significantly with increasing ultrasound power.  
BMP2/7 co-expression is considered highly effective as reported by several in vitro and in vivo studies (Kawai et al., 
2006; Kawai et al., 2009) due to the formation of a highly bioactive BMP2/7 heterodimeric growth factor (Israel et 
al., 1996; Kawai et al., 2009 ), which is less prone to inhibition by endogenous inhibitors (W Zhu, 2006) and 
!∀∋!
!
induces endogenous BMP4 expression (Kawai et al., 2006). By applying this co-expression strategy, we were able 
to achieve 100% bone formation efficacy at lower DNA doses (1/5 of the dose used in (Osawa et al., 2009) with 
BMP2; 1.5x less of the dose used in (Sheyn et al., 2008) with BMP9), lower number of repetitive treatments (5x vs 
7x in (Osawa et al., 2009)) or lower total applied ultrasound power (600 Joule/cm2 in 24h vs. 1500 Joule/cm2 in 24h 
in (Sheyn et al., 2008)) when compared to similar studies using only single BMP gene transfer (Osawa et al., 2009; 
2010; Sheyn et al., 2008). Therefore, we conclude that the selected co-expression strategy is superior to single factor 
expression in the case of BMPs and that this allows higher therapeutic efficacy while using an actual low-efficacy 
non-viral gene transfer method. It might be feasible in the future to enable less invasive sonoporative gene transfer 
to compete with current electroporation approaches (G Pelled, 2005; Kawai et al., 2006; Sheyn et al., 2008), which 
are currently more effective than sonoporation (Sheyn et al., 2008) but rely on invasive insertion of electrodes in 
contrast to minimally invasive transcutaneous application of ultrasound.  
This study employed an internal luciferase control for gene transfer monitoring, which did not exhibit a significant 
detrimental effect on bone formation efficacy (Figure 2A) in the ectopic model. Therefore, we conclude that there is 
no substantial detrimental effect of adding a separate internal control plasmid in this setup. The authors would like to 
note, however, that the luciferase levels obtained in this study were lower than in previously unpublished data for 
single luciferase sonoporation (Hofmann et al. 2013 in preparation), indicating competitive expression between 
internal control plasmids and therapeutic plasmids. In vivo quantitative µCT data showed no significant difference in 
bone volumes or bone mineral densities for passive gene transfer or sonoporation protocols in contrast to bone 
formation efficacy, which is in line with the findings on gene transfer efficacies described above. Bone volumes 
achieved by BMP2/7 gene delivery (passive or sonoporative) were comparable to ectopic bone volumes achieved 
with BMP9 sonoporation in (Sheyn et al., 2008). Average bone mineral densities were within the range of ectopic 
bone mineral densities expected in ectopic bone formation models (Usas et al., 2009; Wijdicks et al., 2009) but 
lower when compared to BMP9 sonoporative gene transfer (Sheyn et al., 2008). Average bone volumes, determined 
in this this study and in (Sheyn et al., 2008) in contrast to other BMP gene delivery work, however, are still limited, 
if compared to approaches which use biomaterials in conjunction with gene delivery or growth factor delivery 
(Bessa et al., 2010; Wegman et al., 2012). This is probably due to the template function of biomaterials, which 
provides a templating environment in contrast to the solution injection approach used in this study. Therefore, it 
might be of interest if ectopic bone volumes could be increased by using sonoporation in conjunction with 
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biomaterials, such as hydrogels. Such an approach for matrix-assisted sonoporation (MAS) has already been 
demonstrated in vitro by our group (Nomikou et al., 2013) and therefore shall be investigated in future studies.  
The observed ectopic bone structures were irregular in shape with multiple centres of ossification per animal (Figure 
3A-F) representing individual foci of gene delivery, expected to be formed due to the chosen multiple injection 
strategy adapted from (Osawa et al., 2009) based on the facto that Osawa et al. (Osawa et al., 2009) and our own 
unpublished data showed that it was impossible to generate ectopic bones by single sonoporation, which indicates 
that gene expression levels obtained are still relatively low and not sufficient for osteoinduction via a single 
treatment. It is thus of great importance to modify the approach to a single gene delivery protocol by using more 
effective therapeutic transgenes in combination with a biomaterial as mentioned above in order to improve and 
spatially control bone formation in vivo. Histological examination the ectopic centres of ossification (Figure 4A, C, 
D) showed functional ectopic bone tissue with calcified compact bone (Figure 4C) surrounding a bone marrow 
cavity (Figure 4D), which hosted haematopoietic bone marrow. This formation of a stem cell niche after BMP gene 
delivery has been reported before (Osawa et al., 2009; Sheyn et al., 2008) and demonstrates that simple gene 
delivery without biomaterials, stem cells or recombinant growth factors can induce the formation of complex tissues 
in vivo. Furthermore, immunohistochemical staining for luciferase (Figure 4B) proved that luciferase recipient cells 
are participating in ectopic bone formation and present in the bone marrow cavity, indicating that endogenous 
transgene receptive cells are contributing to ectopic bone and bone marrow formation. These findings demonstrate 
that direct in vivo co-delivery of bone morphogenetic protein-encoding plasmids can provide a viable alternative to 
stem cell or recombinant protein based therapies. Furthermore, the data presented herein clearly indicates that 
sonoporative gene delivery is superior in direct comparison with passive gene delivery with regards to gene transfer 
probability and that gene transfer efficacies are dependent on the total amount of ultrasound energy applied to the 
target site. 
 
Inducible BMP2/7 co-expression in vivo 
Doxycycline inducible BMP2/7 co-expression from a modified (Feichtinger et al. 2013, under review) bidirectional 
TetON system (Baron U, 1995) showed effective (83% efficacy) bone formation only when applied with ultrasound 
and only if gene expression from the system was activated by systemic application of doxycycline for 7 days (Figure 
2B). This clearly showed tight co-expression control of 2 individual transgenes in vivo by systemic application of an 
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inductor. By narrowing in vivo BMP2/7 co-expression down to approximately 7 days, it was possible to demonstrate 
that even this short time window of in vivo BMP expression, recapitulating endogenous expression patterns (Yu et 
al., 2010), is sufficient for in vivo bone formation. This reduction of therapeutic gene dose and therapeutic gene 
expression time in comparison to the constitutive co-expression systems enabled us to clearly demonstrate the effect 
of sonoporation on bone formation efficacy (Figure 2B). Notably, potentially due to the reduced gene dose and/or 
expression time compared to the constitutive system, it was not possible to induce bone formation by passive gene 
transfer even in animals that received doxycycline treatment. Therefore, we conclude that sonoporation in general 
increases gene transfer efficacy and enables reduction of therapeutic gene dose and therapeutic gene expression time 
due to higher overall gene transfer efficacies & expression, which was not observed as dramatically with the 
constitutive co-expression systems, because overall gene expression levels were probably already saturated in 
contrast to the inducible system.  
 
Orthotopic BMP2/7 sonoporation 
Using X-ray guided repeated DNA injection to the defect site it was possible to achieve spatially controlled gene 
transfer to the target site in vivo without off-target expression in adjacent tissues (Figure 5A-D). Gene transfer 
efficacies were higher when using sonoporation as compared to passive gene transfer (Figure 1C), demonstrating the 
feasibility of using ultrasound for orthotopic gene delivery. Interestingly, in contrast to the ectopic findings, there 
was a significant decrease in luciferase activity when the luciferase plasmid was co-applied with the constitutive 
BMP2/7 co-expression plasmid in passive and sonoporative gene transfer (Figure 1D). This indicates that 
competitive expression might reduce overall gene expression efficacy if multiple independent expression entities are 
applied in vivo. Therefore we based gene transfer efficacy calculations only on the groups, which exclusively 
received the luciferase plasmid to rule out false negative signals observed due to competitive expression in animals 
that received both plasmids. Tracking of plasmid DNA biodistribution at the defect site (Figure 6) using a novel 
metabolic DNA labelling method based on the work of Neef et al. (Neef and Luedtke, 2011) showed a different 
picture than tracking of luciferase gene expression at the target site. It has been observed that the DNA spreads from 
the site of application to unintended tissues such as bone marrow, intact bone and surrounding muscles. Whereas 
expression at these sites could not be evaluated due to the limitations of luciferase imaging, it has been shown by 
other studies that the presence of plasmid DNA at off-target sites does not automatically trigger off-target transgene 
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expression (Coelho-Castelo et al., 2006) and this should therefore be carefully investigated in future studies before 
conclusions about off-target expression can be made. The most striking finding of plasmid DNA biodistribution 
monitoring was the extensive binding of DNA to intact bone indicating that the applied DNA gets absorbed by bone 
tissue. Binding of nucleic acids to ceramic hydroxyapatite has been well known already for some time (Kothari and 
Shankar, 1974; Mazin, 1977) and harnessed for DNA purification (Shan et al., 2012) and delivery (Choi and 
Murphy, 2010; Zhang et al., 2011). This study, however, is the first study to demonstrate this effect in vivo with 
biological hydroxyapatite and naked exogenous DNA in orthopaedic gene delivery. This absorption might be 
considered as another caveat in in vivo naked DNA transfer, additionally to nuclease digestion (Houk et al., 1999; 
Ribeiro et al., 2004) and should be considered in future studies as a parameter potentially responsible for low 
therapeutic efficacy of these approaches in bone regeneration at relatively high doses of DNA (Bonadio et al., 1999; 
Schwabe et al., 2012). In vivo quantitative and qualitative µCT data, although no significant difference could be 
found within this study design, indicate a potential beneficial effect of BMP2/7 gene delivery on regeneration. The 
4mm femur segmental defect model used in this study had an overall non-union rate of 83% at 8 weeks post surgery. 
After in depth µCT evaluation of the empty control group, non-union rate of the model was determined to be 100% 
(0% union rate) and was therefore performing comparably to previous studies in rats by our group (Schmidhammer 
et al., 2006; Schutzenberger et al., 2012). It has been demonstrated that orthotopic BMP2/7 sonoporation leads to 
2/6 confirmed unions (33% union rate) and passive gene delivery could achieve at least 1/6 unions (16% union rate) 
compared to 0/6 unions in both the negative luciferase control and empty defect control groups respectively when 
carefully evaluated by µCT, which has been shown to be the only reliable method in determining union rate 
(Schmidhammer et al., 2006). Therefore, and in conjunction with luciferase data, we conclude that sonoporative 
gene transfer enables orthotopic gene delivery and that orthotopic BMP2/7 sonoporation enhances bone regeneration 
at orthotopic sites. Thus, it might be possible to definitely prove therapeutic efficacy in future studies if the 
therapeutic effect is enhanced significantly either by additional recruitment of cells to a biomaterial in situ prior to 
gene delivery as demonstrated in (Kimelman-Bleich et al., 2011) or by combining our approach with the mentioned 
matrix-assisted sonoporation (MAS) technology (Nomikou et al., 2013). These potential modifications of the current 
protocol address different aspects, which potentially limited the therapeutic efficacy in this study, such as the initial 
lack of expression-capable cells at the defect site and DNA absorption from the target site by the surrounding intact 
bone tissue, given that an additional biomaterial could recruit endogenous cells and retain the therapeutic DNA at 
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the site of action. Furthermore, our data indicated that application of an internal luciferase control reduces gene 
expression at the defect site due to competitive expression. Therefore, therapeutic efficacy could be enhanced in 
future studies by applying only the therapeutic co-expression plasmid without the internal luciferase control. 
 
Non-specific influence of ultrasound on bone regeneration in vivo 
Ultrasound stimulation is a well-known physical method to enhance osteogenic differentiation and bone 
regeneration in vivo. Specifically low-intensity ultrasound stimulation (LIPUS) has successfully been applied for 
this purpose in vitro (Ikeda et al., 2006), in vivo at ectopic sites (Watanuki et al., 2009) and for clinical treatment of 
non-union fractures (Griffin et al., 2008; Romano et al., 2009). Furthermore, it has been documented successfully 
that ultrasound-stimulation in vivo increases the volume of ectopic bone formation with recombinant human BMPs 
in vivo (Wijdicks et al., 2009), thus enabling a reduction in dose using LIPUS. Therefore, it is important to take into 
account potential non-specific effects of ultrasound stimulation on bone for the study described herein. Although 
non-specific effects of ultrasound on bone formation unrelated to gene transfer cannot be ruled out, it is unlikely that 
substantial effects of ultrasound occurred in this study. The ultrasound trigger used for gene delivery is of a different 
frequency (1MHz vs. 1,5Mhz for LIPUS) and uses substantially higher power intensities (90-600 Joule/cm2/day 
compared to approximately 7 Joule/cm2/day in LIPUS) and is considered a high-intensity ultrasound stimulus which 
can lead to tissue heating and damage not occurring in LIPUS treatment (Ikeda et al., 2006). LIPUS itself has 
however been shown to increase the therapeutic efficacy of non-virally delivered BMP expression plasmids 
(Watanuki et al., 2009) in vivo and could therefore be additionally employed in future studies to further increase 
therapeutic efficacy of gene therapeutic approaches. The luciferase control groups employed in this study did not 
show increased bone volumes compared to empty controls, therefore it is unlikely that the employed ultrasound had 
a significant impact on bone regeneration. While it is important to discuss implications of ultrasound stimulation on 
tissue regeneration, we did observed such effects in this study. 
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Figure 1: Influence of sonoporation on orthotopic and ectopic gene transfer efficacies. 
 
Ectopic (A) and orthotopic (C) gene transfer efficacies based on luciferase activity. Ectopic luciferase activity 
(BMP2/7 and luciferase co-delivery) (B) and orthotopic luciferase activity (only luciferase: „pCBR“ vs. luciferase 
and BMP2/7 co-delivery: „pCBR+pVAX1-BMP2/7-„) (D) 24 hours post last gene transfer for passive and 
sonoporative gene delivery. Median ± interquartile range. 
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Figure 2: Enhancement of ectopic bone formation efficacy by sonoporation and effect of doxycycline on 
controlled bone formation (inducible BMP2/7 co-expression system).  
 
Ectopic bone formation efficacies (frequency of successful bone formation after gene delivery) for constitutive 
pVAX1-BMP2/7- based co-expression experiments (A) with and without luciferase plasmid addition (+CBR Luc/-
CBR Luc). Ectopic bone formation efficacies (frequency of successful bone formation after gene delivery) for 
inducible pTetON-BMP2/7 based co-expression experiments (B) without luciferase plasmid addition and with or 
without doxycycline (DOX) application. Results represented for passive gene transfer and 2 Watt/cm2 and 4 
Watt/cm2 sonoporation protocols. 
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Figure 3: BMP2/7 co-expression induces ectopic bone formation in vivo. 
 
Representative images of ectopic bones at 14 days and 28 days post treatment for 4 Watt/cm2 constitutive BMP2/7 
co-expression system sonoporation ("4 Watt/cm2") (A), 2 Watt/cm2 constitutive BMP2/7 co-expression system 
sonoporation ("2 Watt/cm2") (B), 2 Watt/cm2 constitutive BMP2/7 co-expression system sonoporation without 
luciferase internal control ("2 Watt/cm2 (-CBR)") (C), passive gene transfer of the constitutive BMP2/7 co-
expression system ("PASSIVE") (D), passive gene transfer of the constitutive BMP2/7 co-expression system 
without luciferase ("PASSIVE (-CBR)") (E) and inducible BMP2/7 co-expression system without luciferase with 2 
Watt/cm2 sonoporation protocol ("TetON 2 Watt/cm2") (F). Scale bars represent 1mm. Quantitative in vivo µCT 
data for ectopic bones 2 weeks (G) and 8 weeks (H) post treatment. Median ± interquartile range. 
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Figure 4: Formation of ectopic bone and a stem cell niche by BMP2/7 co-expression in vivo.  
 
Histologies of ectopic bone (representative image of 4 Watt/cm2 sonoporation). Haematoxylin/Eosin staining (A), 
Immunohistochemical detection of luciferase (B), von Kossa staining for mineralization (C) and close-up of bone 
marrow of ectopic bones stained with haematoxylin/eosin (D) showing haematopoietic bone marrow with 
haematopoietic stem cells (HSC) and adipocytes (AC). Scale bars represent 50µm, in A, B and C and 20 µm in D. 
 
 
Figure 5: Spatially controlled orthotopic gene delivery in vivo. 
 
Luciferase expression after orthotopic gene delivery. Bioluminescence activity in rat femurs depicted as false colour 
images of average photons/sec/cm2/steradian (A: in vivo; B: in situ; C: ex vivo, femur & adjacent muscle; D: ex 
vivo). 
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Figure 6: Plasmid DNA biodistribution and binding to intact bone in the defect area. 
 
Orthotopic luciferase plasmid tracking using (2'S)-2'-deoxy-2'-fluoro-5-ethynyluridine (F-ara-EdU) metabolically 
labelled pCBR luciferase plasmid DNA detected with Alexa Fluor 680 azide 24 hours post last gene transfer. 
Odyssey near infrared scan of F-ara-EdU signals in a representative femur sample (A), scale bar represents 2mm. 
In-depth examination of selected areas using confocal laser scanning microscopy: femoral bone marrow cavity (B), 
defect granulation tissue (C), intact bone tissue of remaining femur stump (D) and surrounding muscle tissues (E). 
Scale bars represent 100µm. 
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Figure 7: Bone regeneration in femur fractures by orthotopic BMP2/7 sonoporation. 
 
Registered in vivo µCT images of potential unions each from different viewing angles and sagittal cut plane : 0 
weeks (white), 4 weeks (light blue) and 8 weeks post fracture (dark blue) of potential unions in the sonoporation 
therapy group ("SONOBMP") (A), passive gene transfer therapy group ("VECBMP") (B), luciferase sonoporation 
control group ("SONOLUC") (C) and empty control group ("EMPTY") (D). Unions confirmed by in depth 
examination are marked with an asterisk. Scale bars represent 2mm. 
 
 
Figure 8: Effect of orthotopic BMP2/7 sonoporation on union rate. 
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Observed union rates based on in-depth µCT examination (A). Orthotopic bone volumes per defect tissue volumes 
based on quantitative in vivo µCT evaluation 4 weeks (B) and 8 weeks (C) post fracture. Empty control group 
(„Empty“), luciferase control group („pCBR“) and treatment groups („pCBR+pVAX1-BMP2/7-“). Data depicted 
for passive gene transfer („PASSIVE“) and 4 Watt/cm2 sonoporation („4 Watt SONO“). n=6, Median±interquartile 
range. 
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Supplementary Information: Constitutive and Inducible BMP2/7 Co-Expression Plasmids  
Constitutive system pVAX1-BMP2/7- (A): Dual constitutive CMV-promoter cassette based BMP2/7 co- expression 
plasmid with BMP cassettes in divergent orientation. BMP2 cDNA sequence (green), BMP7 cDNA (sequence 
(yellow), CMV-promoter (CMVp, black arrow), bovine growth hormone poly-adenylation signal (BGHpA, black 
box), pUC origin of replication (pUC ori, black box), Kanamycine resistance gene (KanR, white arrow).  
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